Concerning the article recap, stem cell transplant can result in the long-term remission of numerous sclerosis, which are also described as autoimmune diseases. They can make an immune system attack the central nervous system. However, studies show that after receiving treatments such as autologous hematopoietic cell transplant (HCT) and high-dose immunosuppressive therapy (HDIT), more than 60% of the participants managed to survive without experiencing complication such as brain lesions, MS symptoms, and disability. Moreover, no participant took MS Medication after receiving the transplant treatment.

Also, NIAID conducted a trial research known as the HALT-MS experiment. The trial research was funded by ITN (Immune Tolerance Network). The findings of the research results were published in 2014. With the HALT-MS treatment research, researchers tested for durability, efficacy, and safety of HDIT/HCT to 24 volunteers who were of age between 26 and 52 years. The aims of the experiment treatment are to help with the suppression of the active disease and further prevention of the cause of disability. This implies that the primary purpose of HALT-MS experiment is to reset the immune system. It will also help with the prevention of MS symptoms such as chronic pain, weakness, fatigue, and speech difficulties.

About Dr. Shiva GopalVasishta

Dr. Shiva GopalVasishta received her medical skills from the Government Medical College in 1979. He has been in the medical field for 40 years. After completing his studies, Dr. Shiva GopalVasishta managed to finish his residency at the Boston Hospital.Regarding the field of medical expertise, Dr. Shiva GopalVasishta specializes in Neurology and Psychiatry. In that case, Dr. Shiva GopalVasishta currently practices his medical profession at the Eastern Neurodiagnostic Associates. When offering medical services to patients, Dr. Gopal can also accept multiple insurance plans, which include Aetna and Medicare.